Crushed/chewed administration of potent P2Y₁₂ inhibitors in ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Systematic review and meta-analysis

References

• Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol 2016;67(10):1235–1250. doi:10.1016/j.jacc.2015.10.005.
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40(2):87–165. doi:10.1093/eurheartj/ehy394.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045–1057. doi:10.1056/NEJMoa0904327.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Frelinger AL 3rd, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009;30(14):1753–1763. doi:10.1093/eurheartj/ehp159.
   PubMed Web of Science ®Google Scholar
• Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, et al. Angiographic outcomes in the PLATO trial (platelet inhibition and patient outcomes). JACC Cardiovasc Interv 2013;6(7):671–683. doi:10.1016/j.jcin.2013.03.014.
   PubMed Web of Science ®Google Scholar
• Udell JA, Braunwald E, Antman EM, Murphy SA, Montalescot G, Wiviott SD. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv 2014;7(6):604–612. doi:10.1016/j.jcin.2014.01.160.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R. FABOLUS PRO investigators. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (facilitation through aggrastat by drOpping or shortening infusion line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012;5(3):268–277. doi:10.1016/j.jcin.2012.01.006.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5(6):797–804. doi:10.1161/CIRCINTERVENTIONS.112.972323.
   PubMed Web of Science ®Google Scholar
• Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol 2013;61(15):1601–1606. doi:10.1016/j.jacc.2013.01.024.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Cho JR, Bhatti M, DeGroat C, Ferrante E, Dunn EC, Nanavati A, Carraway E, Suryadevara S, et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv 2015;8(11):1457–1467. doi:10.1016/j.jcin.2015.02.030.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, O’Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116(25):2923–2932. doi:10.1161/CIRCULATIONAHA.107.740324.
   PubMed Web of Science ®Google Scholar
• Heestermans AA, Van Werkum JW, Taubert D, Seesing TH, von Beckerath N, Hackeng CM, Schömig E, Verheugt FW, Ten Berg JM. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008;122(6):776–781. doi:10.1016/j.thromres.2008.01.021.
   PubMed Web of Science ®Google Scholar
• Asher E, Frydman S, Katz M, Regev E, Sabbag A, Mazin I, Abu-Much A, Kukuy A, Mazo A, Erez A, et al. Chewing versus swallowing ticagrelor to accelerate platelet inhibition in acute coronary syndrome - the CHEERS study. for the PLATIS (Platelets and Thrombosis in Sheba) study group. Thromb Haemost 2017;117(4):727–733. doi:10.1160/TH16-09-0728.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Gkizas V, Patsilinakos S, Xanthopoulou I, Angelidis C, Anthopoulos P, Makris G, Perperis A, Karanikas S, Koutsogiannis N, et al. Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI. J Am Coll Cardiol 2013;62(10):940–941. doi:10.1016/j.jacc.2013.05.021.
   PubMed Web of Science ®Google Scholar
• Parodi G, Bellandi B, Valenti R, Migliorini A, Marcucci R, Carrabba N, Giurlani L, Gensini GF, Abbate R, Antoniucci D. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the rapid activity of platelet inhibitor drugs (RAPID) primary PCI 2 study. Am Heart J 2014;167(6):909–914. doi:10.1016/j.ahj.2014.03.011.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Makris G, Xanthopoulou I, Patsilinakos S, Deftereos S, Gkizas V, Perperis A, Karanikas S, Angelidis C, Tsigkas G, et al. Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2014;7(2):233–239. doi:10.1161/CIRCINTERVENTIONS.113.001118.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Park Y, Hu J, Kureti M, Rivas Rios J, Faz G, Yaranov D, Been L, Pineda AM, et al. Effects of methylnaltrexone on ticagrelor-induced antiplatelet effects in coronary artery disease patients treated with morphine. JACC Cardiovasc Interv 2019;12(16):1538–1549. doi:10.1016/j.jcin.2019.05.028.
   PubMed Web of Science ®Google Scholar
• Sikora J, Niezgoda P, Barańska M, Buszko K, Skibińska N, Sroka W, Pstrągowski K, Siller-Matula J, Bernd J, Gorog D, et al. METoclopramide administration as a strategy to overcome morphine-ticagrelor interaction in patients with unstable angina pectoris—the metamorphosis trial. Thromb Haemost 2018;118(12):2126–2133. doi:10.1055/s-0038-1675605.
   PubMed Web of Science ®Google Scholar
• Vlachojannis GJ, Vogel RF, Wilschut JM, Lemmert ME, Delewi R, Diletti R, van Vliet R, van der Waarden N, Nuis RJ, Paradies V, et al. Comparison of pre-hospital crushed vs. uncrushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: rationale and design of the COMPARE CRUSH trial. Am Heart J 2020;224:10–16. doi:10.1016/j.ahj.2020.03.005.
   PubMed Web of Science ®Google Scholar
• Gargiulo G, Esposito G, Avvedimento M, Nagler M, Minuz P, Campo G, Gragnano F, Manavifar N, Piccolo R, Tebaldi M, et al. Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment–elevation myocardial infarction. Circulation 2020;142(5):441–454. doi:10.1161/CIRCULATIONAHA.120.046928.
   PubMed Web of Science ®Google Scholar
• Asher E, Tal S, Mazin I, Abu-Much A, Sabbag A, Katz M, Regev E, Chernomordik F, Guetta V, Segev A, et al. Effect of chewing vs swallowing ticagrelor on platelet inhibition in patients with ST-segment elevation myocardial infarction: a randomized clinical trial. JAMA Cardiol 2017;2(12):1380–1384. doi:10.1001/jamacardio.2017.3868.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Barampoutis N, Gkizas V, Vogiatzi C, Tsigkas G, Koutsogiannis N, Davlouros P, Hahalis G, Nylander S, Parodi G, et al. Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic/pharmacodynamic study. Clin Pharmacokinet 2016;55(3):359–367. doi:10.1007/s40262-015-0320-0.
   PubMed Web of Science ®Google Scholar
• Parodi G, Xanthopoulou I, Bellandi B, Gkizas V, Valenti R, Karanikas S, Migliorini A, Angelidis C, Abbate R, Patsilinakos S, et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol 2015;65(5):511–512. doi:10.1016/j.jacc.2014.08.056.
   PubMed Web of Science ®Google Scholar
• Rollini F, Franchi F, Hu J, Kureti M, Aggarwal N, Durairaj A, Park Y, Seawell M, Cox-Alomar P, Zenni MM, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2016;67(17):1994–2004. doi:10.1016/j.jacc.2016.02.045.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39(2):119–177. doi:10.1093/eurheartj/ehx393.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339(jul21 1):b2700. doi:10.1136/bmj.b2700.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol 2018;72(23Pt A):2915–2931. doi:10.1016/j.jacc.2018.09.057.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol 2017;14(6):361–379. doi:10.1038/nrcardio.2017.18.
   PubMed Web of Science ®Google Scholar
• Serenelli M, Pavasini R, Vitali F, Tonet E, Bilotta F, Parodi G, Campo G. Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: systematic review and meta-analysis. J Thromb Haemost 2019;17(6):944–950. doi:10.1111/jth.14434.
   PubMed Web of Science ®Google Scholar
• Haghbayan H, Deif B, Coomes EA. Chewed or crushed administration of adenosine diphosphate receptor inhibitors in acute coronary syndromes: a systematic review and meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther 2020;34(1):139–142. doi:10.1007/s10557-019-06905-w.
   PubMed Web of Science ®Google Scholar
• Fontana P, Roffi M, Reny J-L. Platelet function test use for patients with coronary artery disease in the early 2020s. J Clin Med 2020;9(1):194. doi:10.3390/jcm9010194.
   Web of Science ®Google Scholar
• Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, Catozzi L, Malagutti P, Anselmi M, Vassanelli C, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study. J Am Coll Cardiol 2006;48(11):2178–2185. doi:10.1016/j.jacc.2005.12.085.
   PubMed Web of Science ®Google Scholar
• Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004;110(11):1392–1397. doi:10.1161/01.CIR.0000141575.92958.9C.
   PubMed Web of Science ®Google Scholar
• Rollini F, Franchi F, Cho JR, DeGroat C, Bhatti M, Muniz-Lozano A, Singh K, Ferrante E, Wilson RE, Dunn EC, et al. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur Heart J 2016;37(35):2722–2730. doi:10.1093/eurheartj/ehv744.
   PubMed Web of Science ®Google Scholar
• Parodi G. Ticagrelor administered as standard tablet or orodispersible formulation (TASTER). 2019 January 30. [Accessed 2019 July 8]. https://clinicaltrials.gov/show/NCT03822377
   Google Scholar
• Centro Hospitalario La Concepcion. Pharmacodynamic evaluation of antiplatelet effect of swallowing versus chewing ticagrelor in patients with acute coronary syndrome (TICA-MASTICA). 2020 September 28. [Accessed 2021 July 29]. https://clinicaltrials.gov/show/NCT04567290
   Google Scholar
• Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002. doi:10.1136/bmj.d4002.
   PubMed Web of Science ®Google Scholar